BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities
VANCOUVER, BC / ACCESS Newswire / January 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, is excited to announce a major milestone in its research and development journey. The company is transitioning its cutting-edge R&D activities to the Gen-Plus Contract Research and Development Organization (CRDO) in Munich, Germany, with operations scheduled to begin on March 1, 2025. This move underscores BioNxt's commitment to scientific innovation and advancing solutions for unmet medical needs.
The new laboratory facility provides BioNxt with access to cutting-edge technologies, an expanded 1,000-square-meter research environment, and strategic opportunities for scientific collaboration within Europe's biotech hub. The transition is expected to accelerate the company's ongoing projects, particularly in the areas of drug delivery systems, neurodegenerative disease therapeutics, and next-generation biomedical technologies.
BioNxt Relocates to Gen-Plus: Strategic Importance for Advanced R&D
By leveraging the advanced and innovative infrastructure of the Gen-Plus Laboratory, BioNxt aims to harness the facility's 1,000 square meters of state-of-the-art space designed for high-potency active pharmaceutical ingredients and GMP-compliant processes. The lab's specialized equipment, including advanced technologies for solid and semi-solid dosage forms and capabilities in drug printing, will empower BioNxt to:
Enhance R&D Capabilities: With access to cutting-edge equipment and analytical tools, BioNxt is better positioned to develop innovative solutions and optimize its research outcomes.
Foster Collaborations: The Munich location enables proximity to leading research institutions, biotech firms, and academic experts, paving the way for impactful partnerships.
Accelerate Innovation: The advanced resources at Gen-Plus Laboratory allow BioNxt to streamline workflows and reduce the time to bring groundbreaking therapies to market.
"BioNxt's transition to Gen-Plus marks a pivotal moment for BioNxt," said Hugh Rogers, CEO of BioNxt Solutions Inc. "This transition is both strategic and timely, and unlocking new possibilities for added strength on IP with innovation and reinforcing our mission to deliver transformative therapies for patients worldwide. We are thrilled about the opportunities that this new chapter brings, providing Impact on Current and Future projects."
BioNxt's innovative projects, including the development of advanced drug delivery systems such as sublingual thin films, transdermal patches, and other targeted therapeutic platforms, stand to gain significant advantages from the advanced capabilities at the Gen-Plus Laboratory. This cutting-edge facility is poised to accelerate preclinical research timelines, enhance formulation accuracy, and streamline the development of next-generation therapeutics.
About Gen-Plus GmbH & Co. KG
Gen-Plus GmbH & Co. KG, headquartered in Munich, Germany, is a premier Contract Research and Development Organization (CRDO) with over 25 years of experience in pharmaceutical formulation and development. The company operates a 1,000-square-meter state-of-the-art laboratory equipped for handling high-potency active pharmaceutical ingredients and licensed for GMP-compliant production, including narcotics.
Gen-Plus specializes in developing solid and semi-solid dosage forms, transdermal patches, and oral thin films, offering end-to-end services from feasibility studies to clinical trial supply production. The company leverages advanced technologies such as hot-melt extrusion, drug printing, and amorphization of APIs to deliver comprehensive pharmaceutical solutions.
Committed to innovation, Gen-Plus collaborates with leading European research institutions and biotech companies to drive advancements in pharmaceutical solutions. The company's expertise and cutting-edge infrastructure make it a trusted partner in accelerating drug development and commercialization.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information is based on management's expectations, estimates, projections, and assumptions as of the date of this press release. It is subject to significant risks, uncertainties, and other factors that could cause actual results or events to differ materially from those expressed or implied. These risks and uncertainties include, but are not limited to, general economic conditions, market conditions, regulatory risks, technological advancements, and other factors described in the Company's public disclosure filings.
Readers are cautioned not to place undue reliance on forward-looking information, as actual outcomes may differ significantly from those expressed or implied, due to various factors beyond the Company's control. The Company undertakes no obligation to update or revise any forward-looking information, except as required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Air T, Inc. Announces Closing of Regional Express Acquisition18.12.2025 23:10:00 CET | Press release
MINNEAPOLIS, MN / ACCESS Newswire / December 18, 2025 / Air T, Inc. (NASDAQ:AIRT) is pleased to announce the successful closing of its acquisition of Regional Express Holdings Limited (Rex), Australia's leading regional airline. Air T now owns 100% of Rex and looks forward to beginning a new chapter for Rex and the regional communities it serves across Australia. The transaction includes a comprehensive financing structure designed to support Rex's operations and future growth: Air T is providing a $50 million AUD credit facility that is funded by one of our investor partners. We anticipate that Rex will use this facility to bring its fleet fully back into service, from approximately 31 flyers currently to 45 flyers within the next two years. The Commonwealth of Australia will continue to be a secured creditor of Rex. Rex will have access to an additional undrawn $60 million AUD loan from the Commonwealth of Australia to support the overhaul of its current fleet of Saab 340s and genera
Ascension Advisory Completes Industrial Sale Leaseback in Toledo, Spain on Behalf of OpenGate Capital17.12.2025 23:05:00 CET | Press release
TOLEDO, SPAIN / ACCESS Newswire / December 17, 2025 / Ascension Advisory is pleased to announce the successful closing of an industrial sale leaseback transaction in Toledo, Spain, completed on behalf of Aluminium Solutions Group (ASG), a portfolio company of OpenGate Capital. Aluminium Solutions Group is an industrial manufacturing business specializing in aluminium extrusion and value-added aluminium solutions, serving a range of industrial and commercial end markets across Europe. OpenGate Capital is a global private equity firm specializing in the acquisition and operation of businesses to create new value through operational improvements, innovation and growth. The transaction involved a 44,026 square meter industrial facility situated on a 56,330 square meter site, representing a mission-critical manufacturing asset for ASG's operations in Spain, Extrusiones de Toledo ("EXTOL"). As part of the sale leaseback, EXTOL executed a new long-term triple-net lease, allowing the company t
TruMerit and NAPNAP Team Up to Develop a Global Micro-credential for Pediatric Nursing Care17.12.2025 18:45:00 CET | Press release
PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / December 17, 2025 / TruMerit, a worldwide leader in international credentials evaluation to support health worker careers, and the National Association of Pediatric Nurse Practitioners (NAPNAP), The Leader in Pediatric Education for Nurse Practitioners®, have announced they will jointly develop a global micro-credential to help advance the knowledge and skills of the world's pediatric nursing workforce. The collaboration aims to improve health outcomes for infants, children, adolescents, and young adults worldwide amid a global shortage of pediatric nurses that is limiting access to evidence-based pediatric care in countries of all income levels. The partners envision that their micro-credential program will be the centerpiece of a larger initiative to engage global stakeholders in educating, assessing, and credentialing the nursing workforce in this specialization. A micro-credential is a short, competency-based recognition for specific s
SK tes Achieves NCSC CAS-S Accreditation for Comprehensive Onsite and Offsite Data Destruction and Sanitisation Services Across the UK17.12.2025 15:00:00 CET | Press release
LONDON, UK / ACCESS Newswire / December 17, 2025 / SK tes, a global leader in secure technology lifecycle management, is proud to announce that both its UK sites - Cannock, West Midlands and Irvine, Scotland - have achieved accreditation to the Sanitisation Assurance (CAS-S) Scheme by the UK's National Cyber Security Centre (NCSC) for its secure on-site shredding service. This dual-site accreditation enables SK tes to deliver secure data destruction and sanitisation services nationwide from these two strategic locations, to support clients across the whole of the UK. The CAS-S scheme certifies commercial IT asset sanitisation providers to rigorous government standards, ensuring central government (HMG) customers can easily access services that fully comply with NCSC requirements. With this accreditation, SK tes is authorised to provide: Mobile (offsite) destruction services up to SECRET: Devices are destroyed at the client's premises, ensuring sensitive information never leaves the org
AWM Wraps Up 2025 with Multiple Surf Venue Grand Openings16.12.2025 16:05:00 CET | Press release
Ending the Year on a High Note SOLANA BEACH, CA / ACCESS Newswire / December 16, 2025 / American Wave Machines, the surf technology company behind PerfectSwell® Surf Venues worldwide, concludes banner year with two grand openings and expansion into new markets. São Paulo Surf Club Key Year End Highlights: Riyue Bay: November 11 China Tourism Group celebrated the grand opening of PerfectSwell® Riyue Bay Surf Resort Zion: November 20 The Foundation Ceremony of PerfectSwell® Zion took place in Utah. São Paulo: November 29 JHSF celebrated the grand opening of São Paulo Surf Club "This year's results reflect a herculean effort from the team on improving efficiency, product delivery and commissioning. Finishing with two grand openings in one month is perhaps our most notable achievement. With PerfectSwell® Zion well underway and a third pool starting up in Brazil, 2026 will be just as memorable." - CEO Bruce McFarland "The wave quality achievements made this year have exceeded the expectatio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom